[{"id":"b75ecd93-1120-4cfc-9f9a-b68e1481f48d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588141","created_at":"2022-10-20T14:11:44.038Z","updated_at":"2025-02-25T12:29:09.098Z","phase":"Phase 1/2","brief_title":"A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations","source_id_and_acronym":"NCT05588141","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" IDH1 • IDH2","pipe":" | ","alterations":" IDH2 mutation","tags":["IDH1 • IDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zotiraciclib (TG02)"],"overall_status":"Recruiting","enrollment":" Enrollment 96","initiation":"Initiation: 05/16/2023","start_date":" 05/16/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/02/2029","study_completion_date":" 08/02/2029","last_update_posted":"2025-02-24"},{"id":"9cceceb2-4e58-41ef-ba8e-6eddd7740571","acronym":"","url":"https://clinicaltrials.gov/study/NCT05371054","created_at":"2022-05-12T15:56:31.055Z","updated_at":"2024-07-02T16:34:37.584Z","phase":"Phase 1/2","brief_title":"Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies","source_id_and_acronym":"NCT05371054","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" ALK • BCL2","pipe":" | ","alterations":" MYC rearrangement","tags":["ALK • BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • prednisone • enitociclib (VIP152)"],"overall_status":"Recruiting","enrollment":" Enrollment 130","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 03/10/2025","primary_completion_date":" 03/10/2025","study_txt":" Completion: 03/10/2025","study_completion_date":" 03/10/2025","last_update_posted":"2024-06-06"},{"id":"3f3f38dc-55ac-40c3-bcda-4271d98a6aef","acronym":"","url":"https://clinicaltrials.gov/study/NCT05168904","created_at":"2021-12-23T16:53:47.392Z","updated_at":"2024-07-02T16:35:20.258Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS)","source_id_and_acronym":"NCT05168904","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" BRAF • CDK9","pipe":"","alterations":" ","tags":["BRAF • CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fadraciclib (CYC065)"],"overall_status":"Suspended","enrollment":" Enrollment 210","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 10/01/2024","primary_completion_date":" 10/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-02-08"},{"id":"797d22d8-aa1c-4cc4-b44a-670a2d8ef7a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT04983810","created_at":"2024-01-25T18:19:03.718Z","updated_at":"2024-07-02T16:35:22.250Z","phase":"Phase 1/2","brief_title":"A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma","source_id_and_acronym":"NCT04983810","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" CDK9","pipe":"","alterations":" ","tags":["CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fadraciclib (CYC065)"],"overall_status":"Recruiting","enrollment":" Enrollment 330","initiation":"Initiation: 07/12/2021","start_date":" 07/12/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-01-25"},{"id":"78ef7659-8d3d-4df9-b4a9-a9556d985a98","acronym":"","url":"https://clinicaltrials.gov/study/NCT05159518","created_at":"2021-12-16T14:54:02.338Z","updated_at":"2024-07-02T16:35:26.597Z","phase":"Phase 1","brief_title":"A Study of PRT2527 in Participants With Advanced Solid Tumors","source_id_and_acronym":"NCT05159518","lead_sponsor":"Prelude Therapeutics","biomarkers":" HER-2 • MYC","pipe":" | ","alterations":" HR positive • HER-2 negative • MYC amplification","tags":["HER-2 • MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • MYC amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PRT2527"],"overall_status":"Completed","enrollment":" Enrollment 30","initiation":"Initiation: 02/14/2022","start_date":" 02/14/2022","primary_txt":" Primary completion: 12/06/2023","primary_completion_date":" 12/06/2023","study_txt":" Completion: 12/06/2023","study_completion_date":" 12/06/2023","last_update_posted":"2023-12-11"},{"id":"c9c366ea-e303-45e9-adda-89fe67d98af6","acronym":"VNC-152-101","url":"https://clinicaltrials.gov/study/NCT02635672","created_at":"2021-05-18T17:53:54.105Z","updated_at":"2024-07-02T16:35:39.904Z","phase":"Phase 1","brief_title":"Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer","source_id_and_acronym":"NCT02635672 - VNC-152-101","lead_sponsor":"Vincerx Pharma, Inc.","biomarkers":" MYC","pipe":" | ","alterations":" MYC amplification • MYC expression","tags":["MYC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC amplification • MYC expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • enitociclib (VIP152)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/10/2016","start_date":" 02/10/2016","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2023-08-16"},{"id":"09433bad-7c17-41a7-b1ca-4ac19bbc5a86","acronym":"STEAM","url":"https://clinicaltrials.gov/study/NCT03224104","created_at":"2021-01-18T15:54:47.667Z","updated_at":"2024-07-02T16:36:09.663Z","phase":"Phase 1","brief_title":"Study of TG02 in Elderly Newly Diagnosed or Adult Relapsed Patients With Anaplastic Astrocytoma or Glioblastoma","source_id_and_acronym":"NCT03224104 - STEAM","lead_sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","biomarkers":" IDH1 • IDH2 • MCL1 • CDK9","pipe":" | ","alterations":" IDH1 R132H • IDH1 R132","tags":["IDH1 • IDH2 • MCL1 • CDK9"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH1 R132H • IDH1 R132"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 71","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 05/05/2022","primary_completion_date":" 05/05/2022","study_txt":" Completion: 05/05/2022","study_completion_date":" 05/05/2022","last_update_posted":"2022-05-31"},{"id":"c888a839-4434-4bf4-97af-0865b3e560f8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00999401","created_at":"2021-01-18T03:54:26.432Z","updated_at":"2024-07-02T16:36:19.263Z","phase":"Phase 1","brief_title":"A Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT00999401","lead_sponsor":"Cyclacel Pharmaceuticals, Inc.","biomarkers":" BRCA","pipe":" | ","alterations":" BRCA mutation","tags":["BRCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sapacitabine (CYC682) • seliciclib (CYC202)"],"overall_status":"Completed","enrollment":" Enrollment 103","initiation":"Initiation: 04/01/2009","start_date":" 04/01/2009","primary_txt":" Primary completion: 07/16/2019","primary_completion_date":" 07/16/2019","study_txt":" Completion: 08/13/2019","study_completion_date":" 08/13/2019","last_update_posted":"2021-12-22"},{"id":"9c28c66f-c3b4-4633-96d1-74a5ed78d628","acronym":"","url":"https://clinicaltrials.gov/study/NCT02942264","created_at":"2021-01-18T14:26:49.487Z","updated_at":"2024-07-02T16:36:23.846Z","phase":"Phase 2","brief_title":"Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma","source_id_and_acronym":"NCT02942264","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • ATRX","pipe":"","alterations":" ","tags":["TP53 • ATRX"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e temozolomide • zotiraciclib (TG02)"],"overall_status":"Completed","enrollment":" Enrollment 53","initiation":"Initiation: 12/14/2016","start_date":" 12/14/2016","primary_txt":" Primary completion: 08/26/2020","primary_completion_date":" 08/26/2020","study_txt":" Completion: 08/26/2020","study_completion_date":" 08/26/2020","last_update_posted":"2021-09-28"},{"id":"309d07b0-cac7-4109-a11a-aaa689afa1a1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04493099","created_at":"2021-01-18T21:35:01.887Z","updated_at":"2024-07-02T16:36:38.833Z","phase":"Phase 1/2","brief_title":"Alvocidib in Combination With Decitabine and Venetoclax in Patients With Relapsed or Refractory AML or as Frontline Therapy in Unfit Patients With AML","source_id_and_acronym":"NCT04493099","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • azacitidine • decitabine • alvocidib (DSP-2033)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 10/01/2020","start_date":" 10/01/2020","primary_txt":" Primary completion: 10/12/2020","primary_completion_date":" 10/12/2020","study_txt":" Completion: 10/12/2020","study_completion_date":" 10/12/2020","last_update_posted":"2020-11-11"},{"id":"29b53254-a1d8-4c19-8527-95390b2b9fbb","acronym":"","url":"https://clinicaltrials.gov/study/NCT00005074","created_at":"2021-01-17T22:57:05.986Z","updated_at":"2024-07-02T16:36:46.345Z","phase":"Phase 2","brief_title":"Flavopiridol in Treating Patients With Previously Untreated or Relapsed Mantle Cell Lymphoma","source_id_and_acronym":"NCT00005074","lead_sponsor":"NCIC Clinical Trials Group","biomarkers":" CD20 • CD5","pipe":" | ","alterations":" CD20 positive • CD5 positive","tags":["CD20 • CD5"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD5 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alvocidib (DSP-2033)"],"overall_status":"Completed","enrollment":" Enrollment 33","initiation":"Initiation: 01/24/2000","start_date":" 01/24/2000","primary_txt":" Primary completion: 02/20/2002","primary_completion_date":" 02/20/2002","study_txt":" Completion: 09/22/2008","study_completion_date":" 09/22/2008","last_update_posted":"2020-04-09"},{"id":"a23f867a-7906-432e-89da-e08a603a14c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT01938638","created_at":"2021-01-18T08:46:22.936Z","updated_at":"2025-02-25T17:07:03.748Z","phase":"Phase 1","brief_title":"Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer","source_id_and_acronym":"NCT01938638","lead_sponsor":"Bayer","biomarkers":" MYC • PCNA","pipe":" | ","alterations":" MYC expression • PCNA expression","tags":["MYC • PCNA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MYC expression • PCNA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e atuveciclib (BAY 1143572)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 09/26/2013","start_date":" 09/26/2013","primary_txt":" Primary completion: 08/17/2016","primary_completion_date":" 08/17/2016","study_txt":" Completion: 09/19/2016","study_completion_date":" 09/19/2016","last_update_posted":"2017-10-20"},{"id":"04610283-47d7-4091-9c18-1ccd26727c12","acronym":"","url":"https://clinicaltrials.gov/study/NCT00957905","created_at":"2021-01-18T03:43:42.428Z","updated_at":"2024-07-02T16:37:24.527Z","phase":"Phase 2","brief_title":"Alvocidib and Oxaliplatin With or Without Fluorouracil and Leucovorin Calcium in Treating Patients With Relapsed or Refractory Germ Cell Tumors","source_id_and_acronym":"NCT00957905","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" AFP elevation","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AFP elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • 5-fluorouracil • oxaliplatin • leucovorin calcium • alvocidib (DSP-2033) • fluorouracil topical"],"overall_status":"Completed","enrollment":" Enrollment 36","initiation":"Initiation: 06/01/2009","start_date":" 06/01/2009","primary_txt":" Primary completion: 08/01/2014","primary_completion_date":" 08/01/2014","study_txt":" Completion: 08/01/2014","study_completion_date":" 08/01/2014","last_update_posted":"2017-03-10"}]